<?xml version="1.0" encoding="UTF-8"?>
<p>For COVID-19, it is more logical to find phytomedicinal agents that specifically target the interaction of RBD at the Spike/ACE2 complex and not particular to ACE2. This caution is because agents solely targeting ACE2 may interfere with ACE2 enzyme activity and its complex protective functions (
 <xref rid="B56" ref-type="bibr">Kai and Kai, 2020</xref>). Natural products with significant RBD binding affinity compared to ACE2 can dominate over ACE2 in latching onto RBD, thereby blocking viral attachment, fusion and entry.
</p>
